A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response
A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response
复制标题
DOI：
10.1093/infdis/jiq138
复制
发表时间：
2011-04-01
影响因子：
6.4
通讯作者：
Deeks, Steven G.
中科院分区：
文献类型：
--
作者：
Hatano, Hiroyu;Hayes, Timothy L.;Deeks, Steven G.
背景一些人类免疫缺陷病毒（HIV）感染者尽管长期接受治疗介导的病毒抑制，但仍无法达到正常的CD4（+）T细胞计数。我们进行了一项强化研究，以评估残留的病毒复制是否有助于补充潜在的水库和粘膜HIV特异性T细胞反应是否限制水库的大小。30例CD4（+）T细胞计数≥ 1年的治疗受试者随机接受雷特格韦（400 mg，每日两次）或匹配安慰剂治疗24周。主要终点是血浆病毒血症检测不到的受试者比例（使用超灵敏度测定，检测下限为
Background. Some human immunodeficiency virus (HIV)-infected individuals are not able to achieve a normal CD4(+) T cell count despite prolonged, treatment-mediated viral suppression. We conducted an intensification study to assess whether residual viral replication contributes to replenishment of the latent reservoir and whether mucosal HIV-specific T cell responses limit the reservoir size.Methods. Thirty treated subjects with CD4(+) T cell counts of = 1 year were randomized to add raltegravir (400 mg twice daily) or matching placebo for 24 weeks. The primary end points were the proportion of subjects with undetectable plasma viremia (determined using an ultrasensitive assay with a lower limit of detection of